PB 26 of 2014
National Health (Weighted average disclosed price – supplementary disclosure cycle A) Determination 2014
National Health Act 1953
I, FELICITY MCNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the National Health Act 1953.
Dated:        14 April 2014
 
 
 
 
 
 
 
 
 
FELICITY MCNEILL
 
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health
 
1              Name of Determination
       (1)     This Determination is the National Health (Weighted average disclosed price –supplementary disclosure cycle A) Determination 2014.
       (2)     This Determination may also be cited as PB 26 of 2014.
2              Commencement
                This Determination commences on the day after it is registered.
 
3                   Revocation
  This Determination revokes:
(a)    the National Health (Weighted average disclosed price – supplementary disclosure cycle A) Determination 2013 (PB 24 of 2013);
(b)   the National Health (Weighted average disclosed price – supplementary disclosure cycle B) Determination 2013 (PB 55 of 2013); and
(c)    the National Health (Weighted average disclosed price – main disclosure cycle) Determination 2013 (No. 2) (PB 82 of 2013);
4                   Definitions
In this Determination:
 
Act means the National Health Act 1953.
 
adjusted approved ex-manufacturer price has the same meaning as in subsection 99ADB(1) of the Act.
 
supplementary disclosure cycle A has the same meaning as in regulation 37EB(2)(c) of the National Health (Pharmaceutical Benefits) Regulations 1960.
 
unadjusted price reduction has the same meaning as in subsection 99ADB(1) of the Act. 
                weighted average disclosed price has the same meaning as in subsection 99ADB(1) of the Act.
 
 
5                   Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is at least 10%
 
For subsection 99ADB(4) of the Act, the weighted average disclosed price specified in column 3 of an item in Schedule 1 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 1.
6                   Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is less than 10%
 
For subsection 99ADB(4) of the Act, the weighted average disclosed price specified in column 3 of an item in Schedule 2 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 2.
 
 
7                   Adjusted approved ex-manufacturer price for brands of pharmaceutical items – unadjusted price reduction is at least 10%
 
For paragraph 99ADB(4) of the Act, the adjusted approved ex-manufacturer price for a brand of pharmaceutical item specified in column 2 of Schedule 1 is an amount equal to the amount of the weighted average disclosed price of that brand of pharmaceutical item determined under section 5 of this instrument.
 
 
8                   Reduction Day
 
For paragraph 99ADH(1)(aa) of the Act, a brand of pharmaceutical item in the supplementary disclosure cycle A with a data collection period ending at the end of
31 January 2014 which is mentioned in Schedule 1 or 2 has a reduction day of
1 August 2014.
 
Schedule 1            
Brands of pharmaceutical items – unadjusted price reduction is at least 10%
 
Column 1
Column 2
Column 3

Item
Brand of Pharmaceutical Item
Weighted average disclosed price

 
Drug
Form
Manner of administration
Brand
 

1
Riluzole
Tablet 50 mg
Oral
APO-Riluzole
396.89

2
Riluzole
Tablet 50 mg
Oral
Rilutek
396.89

3
Riluzole
Tablet 50 mg
Oral
Riluzole Sandoz
396.89

Schedule 2              
Brands of pharmaceutical items – unadjusted price reduction is less than 10%
 
Column 1
Column 2
Column 3

Item
Brand of Pharmaceutical Item
Weighted average disclosed price

 
Listed Drug
Form
Manner of administration
Brand
 

1
Amlodipine with valsartan
Tablet 10 mg (as besylate)-160 mg
Oral
Exforge 10/160
17.84

2
Amlodipine with valsartan
Tablet 10 mg (as besylate)-320 mg
Oral
Exforge 10/320
20.92

3
Amlodipine with valsartan
Tablet 5 mg (as besylate)-160 mg
Oral
Exforge 5/160
14.99

4
Amlodipine with valsartan
Tablet 5 mg (as besylate)-320 mg
Oral
Exforge 5/320
18.08

5
Amlodipine with valsartan
Tablet 5 mg (as besylate)-80 mg
Oral
Exforge 5/80
12.53

6
Amlodipine with valsartan
Tablet 5 mg (as besylate)-80 mg
Oral
Valsartan/Amlodipine Sandoz 80/5
12.53

7
Amlodipine with valsartan and hydrochlorothiazide
Tablet 10 mg (as besylate)-160 mg-12.5 mg
Oral
Exforge HCT 10/160/12.5
19.26

8
Amlodipine with valsartan and hydrochlorothiazide
Tablet 10 mg (as besylate)-160 mg-25 mg
Oral
Exforge HCT 10/160/25
20.66

9
Amlodipine with valsartan and hydrochlorothiazide
Tablet 10 mg (as besylate)-320 mg-25 mg
Oral
Exforge HCT 10/320/25
23.76

10
Amlodipine with valsartan and hydrochlorothiazide
Tablet 5 mg (as besylate)-160 mg-12.5 mg
Oral
Exforge HCT 5/160/12.5
16.41

11
Amlodipine with valsartan and hydrochlorothiazide
Tablet 5 mg (as besylate)-160 mg-12.5 mg
Oral
Valsartan/Amlodipine/HCT Sandoz 160/5/12.5
16.41

12
Amlodipine with valsartan and hydrochlorothiazide
Tablet 5 mg (as besylate)-160 mg-25 mg
Oral
Exforge HCT 5/160/25
17.82

13
Imiquimod
Cream 50 mg per g, 2 g, 2
Application
Aldara Pump
102.57

14
Imiquimod
Cream 50 mg per g, 250 mg single use sachets, 12
Application
Aldara
102.57

15
Imiquimod
Cream 50 mg per g, 250 mg single use sachets, 12
Application
APO-Imiquimod
102.57

16
Nevirapine
Tablet 200 mg
Oral
Nevirapine Alphapharm
215.24

17
Nevirapine
Tablet 200 mg
Oral
Nevirapine RBX
215.24

18
Nevirapine
Tablet 200 mg
Oral
Viramune
215.24

19
Nevirapine
Tablet 400 mg (extended release)
Oral
Viramune XR
215.24

Note
1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.comlaw.gov.au.